Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.63 USD
Change Today +0.04 / 2.52%
Volume 738.3K
CUR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

neuralstem inc (CUR) Snapshot

Open
$1.55
Previous Close
$1.59
Day High
$1.68
Day Low
$1.55
52 Week High
06/4/14 - $4.81
52 Week Low
05/20/15 - $1.55
Market Cap
147.2M
Average Volume 10 Days
498.5K
EPS TTM
$-0.25
Shares Outstanding
90.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEURALSTEM INC (CUR)

neuralstem inc (CUR) Related Bloomberg News

View More Bloomberg News

neuralstem inc (CUR) Details

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of all types. Its clinical program products include NSI-566, which is in ongoing Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as in Phase I clinical trial for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; NSI–189 that completed Phase Ia and Ib trials for the treatment of major depressive disorders; and NSI–189, which is in Phase Ib preparation for cognitive deficit in schizophrenia. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

21 Employees
Last Reported Date: 05/8/15
Founded in 1996

neuralstem inc (CUR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $651.2K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $1.2M
Compensation as of Fiscal Year 2014.

neuralstem inc (CUR) Key Developments

Neuralstem, Inc Appoints Jonathan Lloyd Jones as Chief Financial Officer, Effective May 18, 2015; Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Neuralstem, Inc. announced the appointment of Jonathan Lloyd Jones to the position of chief financial officer, effective May 18, 2015. Lloyd Jones brings to the position more than 25 years of corporate finance and business development experience. He previously served as chief financial officer at Columbia Laboratories (Juniper Pharmaceuticals), CFO and VP of corporate development at TetraLogic, and senior director, corporate development at Genzyme Corporation (Sanofi-Aventis). The company also announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the first quarter of 2015, the revenue was $2,917 against $4,167 last year. Operating loss was $4,649,838 against $5,176,901 last year. The decrease in operating loss was primarily attributable to a decrease of approximately $2.1 million in general and administrative expenses largely offset by an increase of approximately $1.6 million in research and development expenses. Interest income was $13,569 against $24,718 last year. Net loss was $5,090,003 against $5,919,057 last year. Basic and diluted net loss per share was $0.06 against $0.07 last year.

Neuralstem, Inc. Reports Consolidated Financial Results for the Full Year Ended December 31, 2014

Neuralstem, Inc. reported consolidated financial results for the full year ended December 31, 2014. For the year, the company reported revenues of $18,833 compared to $110,000 a year ago. Operating loss was $17,435,849 compared to $12,523,941 a year ago. The increase in operating loss was primarily attributable to an increase of approximately $3.7 million in general and administrative expenses coupled with an increase of approximately $1.0 million in research and development expenses. Net loss was $22,628,744 or $0.26 per basic and diluted share compared to $19,831,862 or $0.27 per basic and diluted share a year ago.

Neuralstem, Inc. Announces Topline Results of Phase II ALS Trial

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. Secondary efficacy endpoints at nine months post-surgery indicate a 47% response rate to the stem cell treatment, as measured by either near-zero slope of decline or positive slope of ALSFRS score in seven out of 15 patients and by either a near-zero decline, or positive strengthening, of grip strength in seven out of 15 patients. Grip strength is an indicator of direct muscle strength of the lower arm. ALSFRS is a standard clinical test used to evaluate the functional status of ALS patients. The average ALSFRS score for responders at 9 months after treatment was 37. Non-responders scored an average of 14. These scores represent 93%, versus 35%, of the baseline score retained, respectively, by the responders versus non-responders at 9 months, which is a statistically significant difference. As measured by an average slope of decline of ALSFRS, responders' disease progression was -0.007 point per day, while non-responders' disease progression was -0.1 per day, which was again statistically significant. Lung function as measured by Seated Vital Capacity shows that responder patients remained within 94% of their starting scores, versus 71% for non-responder patients. The trial met its primary safety endpoints. Both the surgery and cells were well-tolerated, with one patient experiencing a surgical serious adverse event.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:US $1.63 USD +0.04

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.71 USD +0.15
Geron Corp $3.93 USD +0.04
International Stem Cell Corp $0.05 USD +0.002
Ocata Therapeutics Inc $6.50 USD -0.40
ReNeuron Group PLC 5.63 GBp +0.375
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8,363.7x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6,293.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEURALSTEM INC, please visit www.neuralstem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.